This is the same comparison as our Semaglutide vs Tirzepatide article, approached from the tirzepatide perspective. Both GLP compounds cover the same trial landscape — this page highlights what makes tirzepatide the higher-efficacy choice and where semaglutide still holds advantages.
Tirzepatide produces more weight loss than semaglutide in every trial that's compared them — roughly 22% vs 15% at respective top doses. This is because the added GIP agonism amplifies the appetite suppression and metabolic effects beyond what GLP-1 alone achieves. Semaglutide's advantages are a longer safety track record (on market since 2017 vs 2022) and more cardiovascular outcome evidence (SELECT trial). For most research focused on maximal metabolic effects, tirzepatide is the stronger compound as of 2026.
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | GLP-1 + GIP | GLP-1 only |
| Mean weight loss (top dose) | ~22.5% | ~14.9% |
| Head-to-head winner | Yes (SURPASS-6) | — |
| Half-life | ~5 days | ~7 days |
| Years on market | ~3 | ~9 (diabetes formulation) |
| Confirmed CV outcome trial | Ongoing (SURPASS-CVOT) | SELECT (2023) confirmed |
| Maximum weekly dose | 15mg | 2.4mg |
SURPASS-6 (2023) directly compared tirzepatide (5, 10, 15mg) against semaglutide 1mg in type 2 diabetes subjects over 40 weeks. All three tirzepatide doses were statistically superior for both weight loss and HbA1c reduction.
| Arm | Weight Loss | HbA1c Reduction |
|---|---|---|
| Semaglutide 1mg | -5.8kg | -1.44% |
| Tirzepatide 5mg | -7.6kg (+31%) | -1.77% |
| Tirzepatide 10mg | -9.3kg (+60%) | -1.98% |
| Tirzepatide 15mg | -11.2kg (+93%) | -2.11% |
The core question was: why does adding GIP agonism produce more weight loss than GLP-1 alone when some earlier research suggested GIP antagonism might be beneficial?
The current understanding involves context-dependence: in obese, insulin-resistant states, GIP receptor activation shifts function. Instead of promoting fat storage (what it does in lean states), it appears to enhance lipid mobilization during caloric deficit and independently suppress appetite via central GIP receptors. The net pharmacological effect is additive on weight loss with a partially buffered GI side effect profile.
Tirzepatide: Higher weight loss ceiling. Better efficacy per injection. The current best-in-class GLP compound available in research supply before retatrutide reaches full market availability.
Semaglutide: More safety data, confirmed CV benefit in non-diabetic population (SELECT), lower cost in most research supply contexts. Appropriate when CV outcomes are the primary research endpoint or when matching STEP trial protocols.